The session drew leaders and experts of many departments of the Vietnamese Health Ministry, as well as Xenothera President Odile Duvaux and CEO Bernard Vanhove.
According to the Ministry of Health, XAV-19 is a COVID-19 treatment drug based on polyclonal antibodies that targets CVID-19 patients with moderate conditions.
The first and second phases of XAV-19 clinical trials’ results showed that the drug is effective and safe in preventing the virus to develop, neutralizing the virus and reducing inflammation in patients.
The third phase of XAV-19 clinical trials is being conducted in some European countries.
Odile Duvaux said that her company is willing to cooperate with Vietnam in implementing the third phase of the trials, and to engage in further discussions on the transfer of the drug production technology to Vietnam.
In May this year, the Ministry of Health and Solidarity of France ordered 30,000 doses of XAV-19 from Xenothera.
Deputy Minister Thuan affirmed Vietnam’s readiness to cooperate with Xenothera in implementing the third phase clinical trials of XAV-19 and receiving technical transfer from the firm.
Following the working session, a Vietnamese firm discussed with Xenothera specific contents in preparation for the signing of a memorandum of understanding on cooperating in the third-phase clinical trials of XAV-19 and technology transfer from the French firm.
